SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Cathcart who wrote (866)3/27/1998 7:02:00 PM
From: seminole   of 1826
 
David

I believe these references for the AACR meeting are significant.
The addition of leukemia cell lines will provide flexablity in selection of studies for Phase II. The combination results are more important. These result will help protect our backside if things go
poorly during Phase II. I EXPECT THE BEST RESULTs (ITS DA BOMB) but
the synergy data gives the company alternatives if problems
develope (this may be Blitzer being prudent). Oh boy, I never though I would be reporting on a less risky alternative.

I got my lucky HMAF t-shirt on
richard
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News